Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001144204-09-037510
Filing Date
2009-07-15
Accepted
2009-07-15 17:27:29
Documents
7
Period of Report
2009-03-31

Document Format Files

Seq Description Document Type Size
1 v154815_10k.htm 10-K 1165877
2 GRAPHIC image1.jpg GRAPHIC 34606
3 v154815_ex21-1.htm EX-21.1 1536
4 v154815_ex31-1.htm EX-31.1 10456
5 v154815_ex31-2.htm EX-31.2 10701
6 v154815_ex32-1.htm EX-32.1 4918
7 v154815_ex32-2.htm EX-32.2 4994
  Complete submission text file 0001144204-09-037510.txt   1247915
Mailing Address 125 MAIDEN LANE, SUITE 309 NEW YORK NY 10038
Business Address 125 MAIDEN LANE, SUITE 309 NEW YORK NY 10038 212-797-9877
Tongli Pharmaceuticals (USA), Inc. (Filer) CIK: 0001052284 (see all company filings)

EIN.: 841090791 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-52954 | Film No.: 09946694
SIC: 7389 Services-Business Services, NEC